Last week, the U.S. Food and Drug Administration approved the newest anti-angiogenesis medication, part of a new family of drugs that revolutionized treatment for patients with kidney cancer. Jack Mydlo, chair of the Department of Urology at Temple University Hospital, says some of his patients have struggled to afford the new therapy: "Even if it's just 10 percent or 20 percent, that goes beyond a lot of people's reach. We have a real battle getting the funding so the patient can fight their disease in a fair battle."